drugset / Trial / NCT00471471

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00471471

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well vaccine therapy works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.

Timeline

Start
2008-10
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NY-ESO-1 Protein / enzyme biologic 100 ug Subcutaneous
Subject agatolimod Oligonucleotide (other) 0.6 mg Subcutaneous
Subject sargramostim Protein / enzyme biologic 80 ug Subcutaneous